LAVA Therapeutics (NASDAQ:LVTX) Earns “Neutral” Rating from HC Wainwright

LAVA Therapeutics (NASDAQ:LVTX)‘s stock had its “neutral” rating reissued by investment analysts at HC Wainwright in a research report issued on Thursday,Benzinga reports. They presently have a $1.50 price target on the stock, down from their prior price target of $2.00. HC Wainwright’s price objective would indicate a potential upside of 11.11% from the company’s previous close.

LVTX has been the subject of a number of other research reports. Citizens Jmp cut LAVA Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, December 11th. JMP Securities reaffirmed a “market perform” rating and issued a $6.00 price target on shares of LAVA Therapeutics in a research note on Wednesday, December 11th. Leerink Partners reaffirmed a “market perform” rating and issued a $2.00 target price (down from $11.00) on shares of LAVA Therapeutics in a research note on Thursday, December 12th. Finally, Leerink Partnrs lowered LAVA Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, December 12th. Five analysts have rated the stock with a hold rating, According to MarketBeat, LAVA Therapeutics currently has an average rating of “Hold” and a consensus target price of $3.17.

LAVA Therapeutics Trading Up 0.7 %

NASDAQ LVTX opened at $1.35 on Thursday. LAVA Therapeutics has a twelve month low of $0.85 and a twelve month high of $6.47. The business’s 50-day moving average price is $0.99 and its 200 day moving average price is $1.44. The company has a market capitalization of $35.49 million, a PE ratio of -1.31 and a beta of 0.57.

LAVA Therapeutics (NASDAQ:LVTX) last posted its quarterly earnings results on Tuesday, December 10th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.11). Equities analysts predict that LAVA Therapeutics will post -1.13 EPS for the current year.

Hedge Funds Weigh In On LAVA Therapeutics

A number of hedge funds have recently modified their holdings of LVTX. Sanofi purchased a new position in LAVA Therapeutics during the 4th quarter worth $1,825,000. BNP Paribas Financial Markets bought a new stake in LAVA Therapeutics in the 4th quarter worth $40,000. Finally, Virtu Financial LLC bought a new position in LAVA Therapeutics in the third quarter worth about $32,000.

About LAVA Therapeutics

LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients.